The Emerging role of lipoprotein(a) in diabetic kidney disease: possible pathophysiological links and unresolved mechanisms

Basit Öğe Kaydı
dc.authorid0000-0003-4056-1673
dc.contributor.authorYaribeygi, Habib
dc.contributor.authorMaleki, Mina
dc.contributor.authorKarav, Sercan
dc.contributor.authorKesharwani, Prashant
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2026-02-03T12:02:45Z
dc.date.available2026-02-03T12:02:45Z
dc.date.issued2026
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractDiabetic kidney disease (DKD) is one of the most serious microvascular complications of diabetes mellitus and a leading cause of end-stage renal disease worldwide. Although hyperglycemia and hypertension are well-established drivers of DKD, accumulating evidence suggests that additional factors, such as lipoprotein(a) [Lp (a)], may contribute to its pathogenesis. Lp(a) is a genetically determined lipoprotein with pro-atherogenic, proinflammatory, and pro-thrombotic properties, and elevated circulating levels have been associated with increased cardiovascular and renal risk in diabetic individuals. In this review, we summarize the current understanding of the relationship between Lp(a) and DKD, with a focus on the proposed molecular mechanisms. These include activation of TGF-beta/Smad signaling leading to fibrosis, induction of oxidative stress, chronic inflammation, endothelial dysfunction, impaired fibrinolysis, and direct injury to podocytes resulting in proteinuria. While several clinical and experimental studies support the involvement of Lp(a) in these pathways, the precise molecular mediators remain largely undefined. Understanding these mechanisms may offer novel insights into the pathophysiology of DKD and identify new therapeutic targets. This article aims to provide a comprehensive overview of the potential role of Lp(a) in DKD and to highlight areas requiring further investigation.
dc.identifier.doi10.1016/j.diabres.2025.113040
dc.identifier.issn0168-8227
dc.identifier.issn1872-8227
dc.identifier.pmid41349613
dc.identifier.scopus2-s2.0-105023901474
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.diabres.2025.113040
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34861
dc.identifier.volume231
dc.identifier.wosWOS:001637729800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofDiabetes Research and Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectDiabetes mellitus
dc.subjectDiabetic kidney disease
dc.subjectLipoprotein(a)
dc.subjectPodocyte injury
dc.subjectFibrosis
dc.subjectOxidative stress
dc.subjectInflammation
dc.subjectTGF-beta/Smad pathway
dc.titleThe Emerging role of lipoprotein(a) in diabetic kidney disease: possible pathophysiological links and unresolved mechanisms
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu